Latest Breaking News On - Fully human - Page 9 : comparemela.com

Message : Required fields Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program ● The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical responses. ● Previous clinical studies in healthy volunteers and COVID-19 patients showed that nasally administered Foralumab is well-tolerated with no apparent severe adverse events (SAEs) when dosed for up to 10 consecutive days. Results from these studies showed strong anti-inflammatory effects of the treatment regimen.

United statesUnited kingdomKunwar shailubhaiHoward weinerGabriele cerroneTanuja chitnisHarvard medical schoolNasal administration of foralumabTiziana life sciencesProfessor of neurology at harvard medical schoolPatient expanded access programRedchip companies incTiziana life sciences announces initiationClinical trialSecondary progressive multiple sclerosisNasal administration